Systematic Serological Screening Programme Used for Strongyloidiasis
|
By LabMedica International staff writers Posted on 13 Nov 2019 |

Image: Strongyloides stercoralis adult. The parasitic female lives threaded into the mucosal epithelium of the human small intestine (Photo courtesy of UVM Ecological Parasitology).
Strongyloidiasis is a soil-transmitted helminth infection caused by the nematode Strongyloides stercoralis and is endemic mainly in tropical and subtropical regions, but also in temperate regions.
This round worm infection is widely extended all over the world and it is estimated that at least 370 million individuals are infected worldwide, with a high degree of endemic burden in the tropical zones, especially Southeast Asia, Sub-Saharan Africa, and Latin America. As strongyloidiasis persists for life, it can cause serious morbidity or death long after an immigrant resettles in a new country.
Scientists at the Hospital de la Cruz Roja (Gijón, Spain) and their colleagues performed a prospective screening programme for strongyloidiasis between 2009 and 2014 for all immigrant patients attending the Tropical Medicine Unit. The patients were classified into seven groups according to their geographical area of origin (Central Africa, East Africa, West Africa, North Africa, Mexico and Central America, South America, and South Asia), following the US Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) criteria.
Three formalin-ether concentrated stool samples and an enzyme-linked immunosorbent assay (ELISA) for anti-S. stercoralis antibodies were used as the screening tools. The qualitative detection of IgG antibodies to S. stercoralis was done using an ELISA (DRG Diagnostics, Marburg, Germany) with microwells coated with Strongyloides antigen. A patient was considered as positive if at least one of the diagnostic tests used for screening (stool samples or/and ELISA) was positive. An eosinophil blood count was performed for all patients. Eosinophilia was defined as >500 eosinophils/mm3.
The team reported that of 659 patients screened, 79 (12%) were positive for S. stercoralis regardless of the diagnostic method used. The prevalence of infection was 42.9% in East African patients, 16.3% in Central African patients, 10.9% in those from South America, and 10% in the case of West Africa. Univariate analysis showed that infection by S. stercoralis was significantly more frequent in patients from Central Africa, and East Africa. Seventy-nine patients had a positive serological test for S. stercoralis; microscopic visualization of larvae of S. stercoralis by formalin-ether concentration of feces was positive for only four of them.
The authors recommended that immigrant patients from developing countries be routinely screened for S. stercoralis, especially those from East Africa. Due to the low sensitivity of stool examination for ova and parasites arising from low larval burden and intermittent shedding in the stool, serological testing is the diagnostic method of choice for screening in immigrant populations. The study was published in the November, 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Hospital de la Cruz Roja
US Centers for Disease Control and Prevention
DRG Diagnostics
This round worm infection is widely extended all over the world and it is estimated that at least 370 million individuals are infected worldwide, with a high degree of endemic burden in the tropical zones, especially Southeast Asia, Sub-Saharan Africa, and Latin America. As strongyloidiasis persists for life, it can cause serious morbidity or death long after an immigrant resettles in a new country.
Scientists at the Hospital de la Cruz Roja (Gijón, Spain) and their colleagues performed a prospective screening programme for strongyloidiasis between 2009 and 2014 for all immigrant patients attending the Tropical Medicine Unit. The patients were classified into seven groups according to their geographical area of origin (Central Africa, East Africa, West Africa, North Africa, Mexico and Central America, South America, and South Asia), following the US Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) criteria.
Three formalin-ether concentrated stool samples and an enzyme-linked immunosorbent assay (ELISA) for anti-S. stercoralis antibodies were used as the screening tools. The qualitative detection of IgG antibodies to S. stercoralis was done using an ELISA (DRG Diagnostics, Marburg, Germany) with microwells coated with Strongyloides antigen. A patient was considered as positive if at least one of the diagnostic tests used for screening (stool samples or/and ELISA) was positive. An eosinophil blood count was performed for all patients. Eosinophilia was defined as >500 eosinophils/mm3.
The team reported that of 659 patients screened, 79 (12%) were positive for S. stercoralis regardless of the diagnostic method used. The prevalence of infection was 42.9% in East African patients, 16.3% in Central African patients, 10.9% in those from South America, and 10% in the case of West Africa. Univariate analysis showed that infection by S. stercoralis was significantly more frequent in patients from Central Africa, and East Africa. Seventy-nine patients had a positive serological test for S. stercoralis; microscopic visualization of larvae of S. stercoralis by formalin-ether concentration of feces was positive for only four of them.
The authors recommended that immigrant patients from developing countries be routinely screened for S. stercoralis, especially those from East Africa. Due to the low sensitivity of stool examination for ova and parasites arising from low larval burden and intermittent shedding in the stool, serological testing is the diagnostic method of choice for screening in immigrant populations. The study was published in the November, 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Hospital de la Cruz Roja
US Centers for Disease Control and Prevention
DRG Diagnostics
Latest Immunology News
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Channels
Clinical Chemistry
view channel
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more
Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
Previous studies have linked vitamin C–rich diets with lower risk of cognitive impairment in older adults. However, few investigations have directly examined blood plasma vitamin C in relation to brain... Read more
Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreMolecular Diagnostics
view channel
Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
Human papillomavirus (HPV)-associated head and neck cancers are frequently treated with surgery, but some patients experience recurrence due to residual microscopic disease. Postoperative decisions about... Read more
New Library Normalization and Amplification Tools Support Oncology Sequencing
High-throughput next-generation sequencing (NGS) laboratories continue to grapple with uneven library pooling and amplification artifacts that can degrade variant calling accuracy and increase reruns.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more








